Natasha Kamal1, Pallavi Surana2, Christopher Koh2. 1. Digestive Diseases Branch. 2. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The aim of this study was to provide an overview of the current understanding of the pathophysiology, diagnosis and management of cystic fibrosis-liver disease (CFLD). RECENT FINDINGS: CFLD has a variety of manifestations. Previously, it was thought that patients progressed from mild cholestatic disease to cirrhosis to decompensated cirrhosis with portal hypertension. Newer evidence suggests that some patients may develop cirrhosis while others develop noncirrhotic portal hypertension. Advances in our understanding of the pathophysiology of disease necessitate modifications to the current diagnostic criteria. Both fibroscan and noninvasive biomarkers can be used to identify patients with cirrhosis and portal hypertension. Ursodeoxycholic acid remains the mainstay of therapy despite a paucity of rigorous studies supporting its use. Novel therapeutic agents such as CF transmembrane conductance regulator (CFTR) modulators and potentiators are encouraging but need to be evaluated specifically in CFLD. SUMMARY: A better understanding of the pathophysiology of disease is critical to developing more disease-specific diagnostics and therapeutics.
PURPOSE OF REVIEW: The aim of this study was to provide an overview of the current understanding of the pathophysiology, diagnosis and management of cystic fibrosis-liver disease (CFLD). RECENT FINDINGS: CFLD has a variety of manifestations. Previously, it was thought that patients progressed from mild cholestatic disease to cirrhosis to decompensated cirrhosis with portal hypertension. Newer evidence suggests that some patients may develop cirrhosis while others develop noncirrhotic portal hypertension. Advances in our understanding of the pathophysiology of disease necessitate modifications to the current diagnostic criteria. Both fibroscan and noninvasive biomarkers can be used to identify patients with cirrhosis and portal hypertension. Ursodeoxycholic acid remains the mainstay of therapy despite a paucity of rigorous studies supporting its use. Novel therapeutic agents such as CF transmembrane conductance regulator (CFTR) modulators and potentiators are encouraging but need to be evaluated specifically in CFLD. SUMMARY: A better understanding of the pathophysiology of disease is critical to developing more disease-specific diagnostics and therapeutics.
Authors: Roderick H J Houwen; Wendy L van der Woerd; Mordechai Slae; Michael Wilschanski Journal: Curr Opin Pulm Med Date: 2017-11 Impact factor: 3.155
Authors: Daniel H Leung; Mahjabeen Khan; Charles G Minard; Danielle Guffey; Louise E Ramm; Andrew D Clouston; Gregory Miller; Peter J Lewindon; Ross W Shepherd; Grant A Ramm Journal: Hepatology Date: 2015-09-28 Impact factor: 17.425
Authors: Jaclyn R Stonebraker; Chee Y Ooi; Rhonda G Pace; Harriet Corvol; Michael R Knowles; Peter R Durie; Simon C Ling Journal: Clin Gastroenterol Hepatol Date: 2016-04-05 Impact factor: 11.382
Authors: Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell Journal: J Pediatr Date: 2008-08 Impact factor: 4.406
Authors: Sylvester M Black; Frederick W Woodley; Dmitry Tumin; Khalid Mumtaz; Bryan A Whitson; Joseph D Tobias; Don Hayes Journal: Dig Dis Sci Date: 2015-11-24 Impact factor: 3.199
Authors: Thomas Flass; Suhong Tong; Daniel N Frank; Brandie D Wagner; Charles E Robertson; Cassandra Vogel Kotter; Ronald J Sokol; Edith Zemanick; Frank Accurso; Edward J Hoffenberg; Michael R Narkewicz Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini Journal: Inflamm Res Date: 2021-04-27 Impact factor: 4.575
Authors: Christina Thornton; Ranjani Somayaji; Michael Parkins; Mark G Swain; Kathleen J Ramos; Christopher H Goss; Abdel A Shaheen Journal: Am J Gastroenterol Date: 2021-08-01 Impact factor: 12.045